Senior Medical Fellow, Pediatric Capabilities
Eli Lilly and Company
Albert J. Allen, MD, PhD, is a senior medical fellow in the Medicines Development Unit at Eli Lilly and Company, where he is the medical lead for pediatric drug development efforts across all therapeutic areas. Dr. Allen received a SB in chemistry and a MS in biochemistry from the University of Chicago in 1980, followed by an MD and PhD in pharmacology from the University of Iowa in 1988. From 1988 to 1995, he completed residencies in psychiatry and child psychiatry at the University of Iowa, and a research fellowship in child psychiatry at National Institute of Mental Health (NIMH). In 1995, he joined the faculty of the Institute for Juvenile Research, Division of Child Psychiatry at the University of Illinois at Chicago (UIC). Dr. Allen was introduced to research ethics through his research at NIMH and his membership on one of UIC’s IRBs. In 2000, he joined the global development organization at Eli Lilly to work on Strattera (atomoxetine HCl, an ADHD medication). He was the global medical director/senior medical director for Strattera from early 2004 until early 2011 and, during much of this time, his responsibilities also included global development efforts for a number of additional neuroscience products and indications. From 2011 to 2013, he was the chair of Eli Lilly’s Bioethics Advisory Committee, and currently serves as a member. From 2011 to 2015, he was a member of SACHRP. Dr. Allen is a member of PRIM&R’s Board of Directors and Public Policy Committee, and is also a member of the AER17 Core Conference Planning Committee.
Friday, November 16
11:15 AM – 12:30 PM